Emerging Peptides for Fat Loss

Introduction

Most newer fat-loss peptides remain at the animal or early human stage. As of October 2026, the strongest new human data come from prescription-drug programs.

Mitochondrial Peptides

MOTS-c

MOTS-c reduced diet-induced obesity in a 2015 mouse study, but as of October 2026 no peer-reviewed study has given it to people. Its analog CB4211 had one 4-week trial in 20 adults with obesity and fatty liver (25 mg daily). Liver enzymes fell, but liver fat dropped as much on placebo. The developer, CohBar, called that formulation unsuitable for further development and moved to dissolve in November 2023.

Modified GH Fragments

AOD-9604 (Current)

Human trials of AOD-9604 used oral or IV dosing only. The largest, OPTIONS (536 adults with obesity, 0.25-1 mg daily by mouth), missed its 12-week weight-loss endpoint, and development stopped in 2007. FDA's December 2024 review found it failed to beat placebo in most studies. Injected use is untested in people; see our AOD-9604 profile.

Melanocortin Peptides

Beyond Melanotan

GLP-1 Related Peptides

Emerging Approaches

Lilly reports five positive Phase 3 trials for the triple agonist retatrutide. In TRIUMPH-4, 12 mg weekly (reached by stepping up from 2 mg) gave 28.7% average weight loss at 68 weeks, versus 2.1% on placebo. Skin tingling or burning (dysesthesia) affected about 4-7% of participants, against about 1% on placebo, in two later trials. As of October 2026 it's unapproved. Lilly plans an FDA filing in Q1 2027 and says retatrutide can't legally be sold for human use, so "research" vials aren't the trial drug.

Relevance to Bodybuilding

Practical Considerations

Where Each Peptide Stands

What to Watch Next

Retatrutide's FDA filing is the next milestone. None of the research-chemical peptides here has a controlled human trial showing fat loss, and vial quality varies; see peptide sourcing and quality control.